All In Biotech

Drug Trial Radar · NCT01104584

Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)

An Open Label, Multi-center, Phase 3 Study With Corresponding Blinded Image Reading to Determine the Efficacy and Safety of a Single Intravenous Injection of 0.1 mmol/kg Body Weight of Gadobutrol 1.0 Molar (Gadovist®) in Patients With Newly Diagnosed Breast Cancer Referred for Contrast-enhanced Breast MRI

Last checked: Nov 19, 2026Latest source record: Nov 11, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

460

Actual

Start

May 2010

Primary completion

Sep 2011

Study completion Jan 2012

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Apr 15, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to look at the efficacy (how does it work) and safety of gadobutrol when used for obtaining MR images of both breasts.Women with a recent diagnosis of breast cancer by mammogram (X-ray examination of the breasts) may benefit from MRI of the breasts as MRI may detect additional breast cancers

Conditions

  • Breast Cancer

Interventions

  • Gadobutrol (Gadavist, Gadovist, BAY86-4875)Drug

    A single bolus injection of gadobutrol 1.0 M; 0.1 mmol/kg body weight

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Difference of Sensitivity for Detection of Full Extent of Malignant Breast Disease Using CMRM vs UMRM Per ReaderTime frame: Immediately before injection and after injection
  2. Sensitivity for Detection of Full Extent of Malignant Breast Disease Using CMRM vs UMRM Per ReaderTime frame: Immediately before injection and after injection
  3. Breast Level Specificity of CMRM for Non-malignant Breasts by ReaderTime frame: Immediately before injection and after injection

Locations

48 sites in 9 countries. Site status is shown where the registry gives one.

  • Site not named

    Tucson, Arizona

  • Site not named

    Oakland, California

  • Site not named

    Englewood, Colorado

  • Site not named

    Chicago, Illinois

  • Site not named

    New York, New York

  • Site not named

    Columbus, Ohio

  • Site not named

    Providence, Rhode Island

  • Site not named

    San Antonio, Texas

  • Site not named

    Tacoma, Washington

  • Site not named

    Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina

  • Site not named

    Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina

  • Site not named

    Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina

  • Site not named

    Hamilton, Ontario, Canada

  • Site not named

    Toronto, Ontario, Canada

  • Site not named

    Toronto, Ontario, Canada

  • Site not named

    Montreal, Quebec, Canada

  • Site not named

    Berlin, Germany

  • Site not named

    Erlangen, Bavaria, Germany

  • Site not named

    München, Bavaria, Germany

  • Site not named

    Frankfurt am Main, Hesse, Germany

  • Site not named

    Göttingen, Lower Saxony, Germany

  • Site not named

    Göttingen, Lower Saxony, Germany

  • Site not named

    Greifswald, Mecklenburg-Vorpommern, Germany

  • Site not named

    Bochum, North Rhine-Westphalia, Germany

  • Site not named

    Münster, North Rhine-Westphalia, Germany

  • Site not named

    Münster, North Rhine-Westphalia, Germany

  • Site not named

    Gera, Thuringia, Germany

  • Site not named

    Delhi, India

  • Site not named

    Mumbai, India

  • Site not named

    Mumbai, Maharashtra, India

  • Site not named

    Maastricht, Netherlands

  • Site not named

    Nijmegen, Netherlands

  • Site not named

    Eindhoven, EJ, Netherlands

  • Site not named

    Bydgoszcz, Poland

  • Site not named

    Gliwice, Poland

  • Site not named

    Krakow, Poland

  • Site not named

    Szczecin, Poland

  • Site not named

    Warsaw, Poland

  • Site not named

    Córdoba, Spain

  • Site not named

    Barcelona, Barcelona, Spain

Showing 40 of 48 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.